Sugi Predict

Sugi Predict / Compounds / SCHEMBL9937183

SCHEMBL9937183

SCHEMBL9937183

C=CCN[C@@H]1CCCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ EPHX1 P07099 1/20 0.47
▸ USP30 Q70CQ3 2/20 0.47
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ HPGD P15428 1/20 0.43
▸ FPR2 P25090 2/20 0.43
▸ FPR3 P25089 1/20 0.43
▸ HDAC4 P56524 1/20 0.41
▸ HDAC6 Q9UBN7 1/20 0.41
▸ BRD4 O60885 1/20 0.41
▸ PARP1 P09874 1/20 0.41
▸ GLS O94925 1/20 0.40
▸ KDM1A O60341 1/20 0.39
▸ ACKR3 P25106 1/20 0.39
▸ ANO1 Q5XXA6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1439214 1.00 MEN1 (0.48) MEN1ALDH1A1MAPTKMT2AEPHX1
SCHEMBL6900671 0.84 MEN1 (0.52) MEN1ALDH1A1MAPTKMT2AEPHX1
SCHEMBL4023236 0.84 EPHX1 (0.55) ALDH1A1MAPTKMT2AEPHX1CA1
SCHEMBL2729153 0.83 USP30 (0.52) MEN1ALDH1A1MAPTKMT2AEPHX1
SCHEMBL28779716 0.83 USP30 (0.52) MEN1ALDH1A1MAPTKMT2AEPHX1
SCHEMBL1420850 0.83 ALDH1A1 (0.51) MEN1ALDH1A1MAPTKMT2AEPHX1
SCHEMBL12991276 0.83 ALDH1A1 (0.51) MEN1ALDH1A1MAPTKMT2AEPHX1
SCHEMBL6128815 0.83 USP30 (0.52) MEN1ALDH1A1MAPTKMT2AEPHX1
SCHEMBL2894275 0.83 ALDH1A1 (0.51) MEN1ALDH1A1MAPTKMT2AEPHX1
SCHEMBL994411 0.82 MEN1 (0.46) MEN1ALDH1A1MAPTKMT2AEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240246988-A1 BRUTON'S TYROSINE KINASE INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2024-07-25 — — US disclosed
CN-112300172-B Bruton tyrosine kinase inhibitors 比奥根MA公司 2024-01-16 — — CN disclosed
US-20230046457-A1 BRUTON'S TYROSINE KINASE INHIBITORS BIOGEN MA INC. 2023-02-16 — — US disclosed
US-20230046457-A1 BRUTON'S TYROSINE KINASE INHIBITORS BIOGEN MA INC. 2023-02-16 — — US disclosed
CN-112300172-A Bruton's tyrosine kinase inhibitors 比奥根MA公司 2021-02-02 — — CN disclosed
US-20200399283-A1 BRUTON'S TYROSINE KINASE INHIBITORS VIRACTA THERAPEUTICS, INC. 2020-12-24 — — US disclosed
US-20200399283-A1 BRUTON'S TYROSINE KINASE INHIBITORS VIRACTA THERAPEUTICS, INC. 2020-12-24 — — US disclosed
CN-107011330-B Bruton's tyrosine kinase inhibitors 比奥根MA公司 2020-07-03 — — CN disclosed
US-10577374-B2 Bruton's tyrosine kinase inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2020-03-03 — — US disclosed
US-10577374-B2 Bruton's tyrosine kinase inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2020-03-03 — — US disclosed
US-20140309212-A1 BRUTON'S TYROSINE KINASE INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2014-10-16 — — US disclosed
US-20140309212-A1 BRUTON'S TYROSINE KINASE INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2014-10-16 — — US disclosed
US-8785440-B2 Bruton's tyrosine kinase inhibitors BIOGEN IDEC MA, INC. (US) 2014-07-22 — — US disclosed
US-8785440-B2 Bruton's tyrosine kinase inhibitors BIOGEN IDEC MA, INC. (US) 2014-07-22 — — US disclosed
US-8785440-B2 Bruton's tyrosine kinase inhibitors BIOGEN IDEC MA, INC. (US) 2014-07-22 — — US disclosed
CN-102711473-A Bruton's tyrosine kinase inhibitors BIOGEN IDEC INC 2012-10-03 — — CN disclosed
US-20120157443-A1 BRUTON'S TYROSINE KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2012-06-21 — — US disclosed
US-20120157443-A1 BRUTON'S TYROSINE KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2012-06-21 — — US disclosed
US-20120157443-A1 BRUTON'S TYROSINE KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2012-06-21 — — US disclosed
WO-2011029046-A1 BRUTON'S TYROSINE KINASE INHIBITORS BIOGEN IDEC MA INC. (US) 2011-03-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246988-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK MEN1 3176/4885ALDH1A1 4783/4885MAPT 4120/4885
US-20230046457-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK MEN1 3176/4885ALDH1A1 4783/4885MAPT 4120/4885
US-20140309212-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK MEN1 3176/4885ALDH1A1 4783/4885MAPT 4120/4885
US-20200399283-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK MEN1 3176/4885ALDH1A1 4783/4885MAPT 4120/4885
US-20120157443-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK MEN1 3176/4885ALDH1A1 4783/4885MAPT 4120/4885
US-10577374-B2 Bruton's tyrosine kinase inhibitors BTK, ABL1, SYK MEN1 3176/4885ALDH1A1 4783/4885MAPT 4120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.